Bernard 1999

Methods	n = 60 Allocation concealment: not described Baseline similarity: "comparable" except for presence of shock (more common in treatment group) Blinding: caregivers Cointerventions: not described Withdrawals: none Losses to follow‐up: none
Participants	Inclusions: Mechanical ventilation; AECC definition for ALI and ARDS; duration of ALI or ARDS < 36 hours Exclusions: Neurologic disease impairing weaning; chronic lung disease; morbid obesity; liver disease; immunocompromised; burns; increased intracranial pressure
Interventions	IV interleukin‐10, 8 mcg/kg or 20 mcg/kg IV daily for 6 days, or placebo
Outcomes	28 day mortality (both doses of interleukin‐10 versus control): RR 0.68 (95% CI 0.26 to 1.76) Ventilator free days to day 28 (not stated if mean or median): 15 (8 mcg/kg group); 6 (20 mcg/kg group); 9 (placebo group); p value not given Adverse events leading to discontinuation of therapy: none
Notes	Published only as abstract
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear